首页> 外文期刊>Implementation Science >Triage, treatment and transfer of patients with stroke in emergency department trial (the T3 Trial): a cluster randomised trial protocol
【24h】

Triage, treatment and transfer of patients with stroke in emergency department trial (the T3 Trial): a cluster randomised trial protocol

机译:中风患者在急诊课程审判中的患者进行分类,治疗和转移(T3审判):一组随机试验方案

获取原文
           

摘要

Internationally recognised evidence-based guidelines recommend appropriate triage of patients with stroke in emergency departments (EDs), administration of tissue plasminogen activator (tPA), and proactive management of fever, hyperglycaemia and swallowing before prompt transfer to a stroke unit to maximise outcomes. We aim to evaluate the effectiveness in EDs of a theory-informed, nurse-initiated, intervention to improve multidisciplinary triage, treatment and transfer (T3) of patients with acute stroke to improve 90-day death and dependency. Organisational and contextual factors associated with intervention uptake also will be evaluated. This prospective, multicentre, parallel group, cluster randomised trial with blinded outcome assessment will be conducted in EDs of hospitals with stroke units in three Australian states and one territory. EDs will be randomised 1:1 within strata defined by state and tPA volume to receive either the T3 intervention or no additional support (control EDs). Our T3 intervention comprises an evidence-based care bundle targeting: (1) triage: routine assignment of patients with suspected stroke to Australian Triage Scale category 1 or 2; (2) treatment: screening for tPA eligibility and administration of tPA where applicable; instigation of protocols for management of fever, hyperglycaemia and swallowing; and (3) transfer: prompt admission to the stroke unit. We will use implementation science behaviour change methods informed by the Theoretical Domains Framework [1, 2] consisting of (i) workshops to determine barriers and local solutions; (ii) mixed interactive and didactic education; (iii) local clinical opinion leaders; and (iv) reminders in the form of email, telephone and site visits. Our primary outcome measure is 90?days post-admission death or dependency (modified Rankin Scale 2). Secondary outcomes are health status (SF-36), functional dependency (Barthel Index), quality of life (EQ-5D); and quality of care outcomes, namely, monitoring and management practices for thrombolysis, fever, hyperglycaemia, swallowing and prompt transfer. Outcomes will be assessed at the patient level. A separate process evaluation will examine contextual factors to successful intervention uptake. At the time of publication, EDs have been randomised and the intervention is being implemented. This theoretically informed intervention is aimed at addressing important gaps in care to maximise 90-day health outcomes for patients with stroke. Australian and New Zealand Clinical Trials Registry ACTRN12614000939695 . Registered 2 September 2014.
机译:国际认可的基于证据指导方针建议在急诊部门(EDS)中卒中患者的适当分类,组织纤溶酶原激活剂(TPA),并在及时转移到行程单元之前进行发烧,高血糖和吞咽以最大化结果。我们的目标是评估EDS的效果,以改善急性中风患者的多学科分类,治疗和转移(T3),以改善90天的死亡和依赖。还将评估与干预吸收相关的组织和上下文因素。这种预期,多期中心,并联集团,与盲目成果评估的集群随机试验将在三个澳大利亚国家和一个领土中的中风单元进行。 EDS将在状态和TPA卷定义的地层中随机1:1接收T3干预或无需额外支持(控制EDS)。我们的T3干预包括基于证据的护理束靶向:(1)分类:涉嫌涉嫌患者的常规分配到澳大利亚分馏等级1或2类; (2)治疗:筛选TPA资格和TPA的管理;对发烧,高血糖和吞咽的管理方案的灌注;和(3)转让:提示入院单位。我们将使用由(i)研讨会的理论域框架[1,2]通知的实现科学行为改变方法,以确定障碍和本地解决方案; (ii)混合互动和教学教育; (iii)地方临床意见领导人; (iv)以电子邮件,电话和现场访问的形式提醒。我们的主要结果措施是90?天后期死亡或依赖性(改进的Rankin Scale> 2)。二次结果是健康状况(SF-36),功能依赖(Barthel指数),生活质量(EQ-5D);和护理质量,即溶栓,发热,高血糖,吞咽和及时转移的监测和管理实践。结果将在患者水平评估结果。单独的过程评估将研究成功干预吸收的上下文因素。在出版时,EDS已被随机化,并正在实施干预。理论上的干预措施旨在解决重要的差距,以便为中风患者最大限度地提高90天的健康结果。澳大利亚和新西兰临床试验登记法ACRRN12614000939695。注册2014年9月2日。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号